Tirzepatide
A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity
Eli Lilly · Phase 2 · Completed · Enrollment 392
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Tirzepatide (TZP) + Mibavademab (MIBA) [Group A] | n/r | n/r | n/r | n/r | n/r |
| TZP + Mibavademab-placebo (MIBA-PBO) [Group B] | n/r | n/r | n/r | n/r | n/r |
| TZP + MIBA then Tirzepatide-placebo (TZP-PBO) + MIBA [Group C] | n/r | n/r | n/r | n/r | n/r |
| TZP + MIBA [Group D] | n/r | n/r | n/r | n/r | n/r |
| TZP + MIBA-PBO [Group E] | n/r | n/r | n/r | n/r | n/r |
| TZP + MIBA-PBO then TZP-PBO + MIBA [Group F] | n/r | n/r | n/r | n/r | n/r |
| TZP + MIBA-PBO then TZP + MIBA [Group G] | n/r | n/r | n/r | n/r | n/r |
| TZP + MIBA-PBO then TZP-PBO + MIBA-PBO [Group H] | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.